Manufacturing News of Note—Lonza expands cell therapy facility; Mylan recalls anxiety drug

> Mylan is voluntarily recalling more than 10,000 bottles of generic Xanax, saying there is a small risk from a foreign substance. Release

> Lonza says it will expand its Singapore cell therapy operation and use new technology to produce commercial-scale product of an allogeneic cell treatment being developed by Mesoblast the biotech expects to submit to the FDA for review by the end of the year. Release

> The FDA has posted a warning letter to Glenmark that the Indian drugmaker earlier this month reported it had received. Warning letter

> U.K.-based CDMO Sterling Pharma is investing $1.5 million in a plant in Research Triangle Park, North Carolina, that it acquired earlier this year. 

> China’s API maker WuXi Sta say its manufacturing facility in Jinshan in Shanghai has passed a European Medicines Agency inspection. Release 

> There have been shortages in hormone replacement therapy in the U.K. Release 

> CPI and Strathclyde University, in a partnership with GlaxoSmithKline and AstraZeneca, have begun work on a continuous direct compression platform for oral solid dose meds. Story 

> India's Lupin, which has a long list of FDA manufacturing issues, says its plant in Nagpur passed an inspection with no observations. Release

> Taiwanese CDMO Bora, which specializes in complex modified release products, has opened a U.S. office in Delaware. Release